arrow_back Trending Legislation
Share share

Marihuana and CBD Research Expansion: New Rules and Access

This act simplifies scientific research on marihuana and cannabidiol (CBD), potentially accelerating drug development. It modifies registration rules for researchers and manufacturers, ensuring better access to these substances for medical purposes. Citizens can anticipate more research into the potential medical uses of marihuana and CBD.
Key points
Streamlining the process for researchers and institutions to obtain approval for marihuana research.
Increasing the availability of marihuana and CBD for research and the production of FDA-approved drugs.
Physicians can freely discuss the potential benefits and harms of marihuana and its derivatives with patients (or their guardians).
The federal government will conduct and coordinate research on the effects of marihuana and CBD on health, including on adolescent brains and cognitive abilities.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Cannabidiol and Marihuana Research Expansion Act
Print number: S 253
Sponsor: Sen. Feinstein, Dianne [D-CA]
Process start date: 2021-02-04
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Marihuana and CBD Research Expansion: New Rules and Access

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is S 253.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2021-02-04.

What are the main provisions?

Key points include:

  • Streamlining the process for researchers and institutions to obtain approval for marihuana research.
  • Increasing the availability of marihuana and CBD for research and the production of FDA-approved drugs.
  • Physicians can freely discuss the potential benefits and harms of marihuana and its derivatives with patients (or their guardians).
  • The federal government will conduct and coordinate research on the effects of marihuana and CBD on health, including on adolescent brains and cognitive abilities.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Feinstein, Dianne [D-CA].

What is the latest detailed status?

The latest detailed status is: Passed Senate with an amendment by Unanimous Consent. (text of amendment in the nature of a substitute: CR S1781-1783)

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2026-01-02.

Analysis and Potential Impact of S 253

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health Courts and Law